LCTX Short Volume
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $318.8M, listed on AMEX, employing roughly 70 people, carrying a beta of 1.60 to the broader market. Lineage Cell Therapeutics, Inc. Led by Brian Culley, public since 1992-03-05.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 282.0K
- Total Volume
- 565.1K
- Short %
- 49.91%
- 30-Day Avg Short %
- 41.53%
Showing 30 days of FINRA short volume data for Lineage Cell Therapeutics, Inc..
Learn how short volume is reported and how to read the data →
Frequently asked LCTX short volume questions
- What is the daily LCTX short volume?
- As of May 15, 2026, Lineage Cell Therapeutics, Inc. (LCTX) short volume is 282.0K shares against 565.1K total reported volume, or 49.91% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is LCTX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does LCTX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.